Pioneering the Nonprofit Pharmaceutical Industry

Medicines360 is a nonprofit women’s health pharmaceutical company in San Francisco. As a nonprofit, we answer to our mission: to remove cost as a barrier to health by developing and providing quality, affordable women’s health products. We were founded in 2009 and brought our first product to the U.S. market in 2015.

We’re proud of our success in bringing products to the market through innovative partnerships. We have partnered with a for-profit biopharmaceutical company in the U.S. to offer our product to 340B-enrolled clinics and hospitals at a price substantially below the 340B ceiling price set by statute. We believe that our efforts have resulted in estimated savings to 340B-enrolled sites and the low-income and uninsured patients they serve of $54 million since April 2015.*

We’re also working to help ensure that women in low- and middle-income countries have access to our product through our Avibela Project, in partnership with organizations including WCG Cares, Population Services International, Marie Stopes International, and DKT International.

Our unique nonprofit pharmaceutical model allows us to focus on the most vulnerable patients:

  1. Uninsured: 8.5% of Americans (27.5 million people) were uninsured for the full 2018 calendar year. Because these patients often pay out-of-pocket, they are particularly sensitive to cost. Development of low-cost options can be the difference between access and no access to the medications these patients may need.
  2. Underinsured: Even with insurance, many Americans cannot afford the medicines they need. Patients frequently cite the high out-of-pocket cost of prescription drugs for not taking medicines as scheduled or not being able to get them in the first place. In addition, some insured people have no coverage for certain preventative services. For these patients, lower drug costs are critical to enable access.

Components of Medicines360’s pioneering mission-driven approach include the following:

  1. Our nonprofit business model. Medicines360 is a Medical Research Organization, a public charity exempt from Federal income tax under Section 501(c)(3) of the U.S. Tax Code. We operate exclusively for charitable purposes and benefit from the oversight of an independent board of directors. By removing traditional shareholder profit requirements, we can focus on public benefit as our bottom line.
  2. Expertise in drug-device product design and development. We have experience in scaling clinical trials to study our product in subjects that accurately reflect the U.S. population. We also have ongoing research and development activities involving other women’s health products.
  3. Our public sector engagement. Medicines360’s engagement team focuses on the public sector, ensuring that 340B-enrolled clinics and hospitals have the information and resources needed to care for their patients. We estimate over 1,500 340B sites have accessed our product for the women they serve.
  4. Knowledge of pharmaceutical and public health policy. Through our experience bringing a product to market as a nonprofit pharmaceutical company, we have identified potential changes to complex federal and state policies that could expand affordable access to medicines for women.

American drug pricing is a complex and bipartisan issue, with both Democrats and Republicans evaluating ways to reduce spending. In 2018, The U.S. Department of Health and Human Services issued the American Patients First blueprint, a comprehensive plan to bring down prescription drug prices and out-of-pocket costs.

Over the last ten years, we’ve thrived at the intersection of nonprofit public health, pharmaceutical research and development, and health policy. Medicines360 is positioned to build on our wealth of experience and leverage our expertise to increase access to medicines for all Americans.

* Data on file. Medicines360: San Francisco, CA.

About Medicines360

Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical organization with a mission to catalyze equitable access to medicines and devices through product development, policy advocacy, and collaboration with global and US partners. Medicines360, through its subsidiary Impact RH360, launched the Avibela Project to expand access to hormonal IUDs in low- and middle-income countries. For more information, visit medicines360.org

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.